Business
OptimizeRx Named America’s Fastest-Growing Company for Fifth Year in a Row
Market Embraces Disruptive AI-Powered Capabilities WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a
About this update from Optimizerx Corporation
[{"type":"text","content":"Market Embraces Disruptive AI-Powered Capabilities\nWALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has secured a coveted spot on the 2024 Financial Times’ Americas’ Fastest-Growing Companies list for a remarkable fifth consecutive year, ranking at 253. The Americas’ Fastest Growing Companies 2024 ranking identifies companies with the strongest revenue growth between the years 2019 and 2022. OptimizeRx’s 36% growth during that time-period was fueled by a “land and expand” strategy. The Company gained momentum with new life sciences clients while also expanding its footprint with existing customers by introducing new offerings, such as its RWD.AI solution (known as Dynamic Audience Activation Platform today) and supporting new branded medications. Market Embraces Disruptive DAAP Platform OptimizeRx's impressive growth trajectory is further fueled by the market's strong adoption of its proprietary Dynamic Audience Activation Platform (DAAP). The AI (Artificial Intelligence)-enabled platform delivers predictive and privacy-safe marketing solutions, designed to connect life sciences, HCPs, and patients across the most robust network of personal and clinical platforms. DAAP serves as a single source for life sciences organizations seeking to enhance the reach and effectiveness of their HCP and DTC healthcare marketing efforts. This robust platform positions OptimizeRx as a clear leader in data-driven healthcare engagement. Leveraging real-world data and predictive modeling-empowered algorithms, DAAP compliantly predicts the time window when a patient becomes eligible for specific treatments, enabling earlier brand outreach and treatment initiation. This translates to significant revenue growth potential for life science partners. \"This five-year streak on the Financial Times list is a powerful signal of the market demand for our innovative capabilities,\" said Will Febbo, OptimizeRx CEO.\" Our newest enhancement, DAAP, has the potential to significantly improve patient outcomes by enabling earlier treatment initiation while streamlining healthcare delivery. This translates to a win-win scenario for both patients and the healthcare syst...